Weekly Rundown: Key Catalysts for Small-Cap Stocks (October 13–17)

From recent disclosures to corporate shifts, we’ve highlighted the top small-cap catalysts to watch. Here’s your weekly preview (October 13-17).

--

Companies Presenting at the European Society for Medical Oncology (ESMO) Congress 2025:

Berlin, Germany | 17–21 October 2025

● IMMP announced three accepted abstracts on its first-in-class MHC Class II agonist, eftilagimod alfa (efti). Highlights include a Proffered Paper on the Phase II EFTISARC-NEO trial in soft tissue sarcoma, a poster on the Phase I INSIGHT-003 trial in first-line NSCLC, and an ePoster on the pivotal Phase III TACTI-004 study. Presentations are scheduled for October 18 and 19.

● AGEN will showcase multiple presentations on its immunotherapy combination of botensilimab and balstilimab, including an oral presentation featuring emerging survival data from 343 patients with refractory metastatic solid tumors. Three additional posters will cover studies in cervical cancer, MSS mCRC, and non-melanoma skin cancers (October 17–20).

● EVAX will present two-year efficacy results from its Phase II trial of EVX-01, a personalized cancer vaccine for advanced melanoma, showing strong T-cell responses and durable disease control. The mini oral session is on October 17 at 14:10 CEST.

● NCNA will share data revealing synergy between NUC-7738 and PD-1 inhibition in renal cell cancer during a poster session (No. 1530P) on October 19.

● CATX will present updated results from its [212Pb]VMT-α-NET program in targeted radiopharmaceutical therapy on October 20.

● KAPA will highlight interim results from a Phase II study of apalutamide and carotuximab (ENV105) in advanced castration-resistant prostate cancer. The trial evaluates safety and efficacy in 100 men enrolled across major U.S. cancer centers.

● LPTX will present data from the Phase II DeFianCe trial testing sirexatamab (DKN-01) with bevacizumab and chemotherapy in advanced MSS colorectal cancer. The mini oral presentation by Dr. Zev Wainberg (UCLA) is on October 19 at 16:05 CEST.

● IOBT will present Phase III results for its IO102-IO103 (IDO/PD-L1) vaccine plus pembrolizumab in first-line advanced melanoma during an oral session on October 20. Final Phase II basket trial results in solid tumors will also be presented on October 19.

● NUVB will share findings from the TRUST-II study evaluating taletrectinib in ROS1-positive NSCLC patients previously treated with entrectinib. The poster presentation by Dr. Filippo De Braud (University of Milan) is on October 18.

● CGEN will present pooled data from three Phase I trials of COM701 in platinum-resistant ovarian cancer. The poster, led by Dr. Oladapo Yeku (Massachusetts General Hospital), is scheduled for October 18.

Companies Attending the 2025 Association of the United States Army (AUSA) Annual Meeting & Exposition:

Washington, D.C. | October 13–15, 2025 | Walter E. Washington Convention Center

● KOPN  • BURU  • MTEK  • OSS

Companies Participating at the Capital Link's 17th Annual New York Maritime Forum (NYMF):

New York, NY | October 14, 2025 | Metropolitan Club

SB  • DSX  • TORO  • CTRM  • USEA  • PANL

Companies Participating in the Fireside Chat at the H.C. Wainwright Genetic Medicines Virtual Conference:

Virtual | October 14–15, 2025

TNYA   • EDIT   • PRME

Additional Companies with Material Events This Week:

● AREB → Announced participation in the 2025 National Beer Wholesalers Association (NBWA) Annual Convention and Trade Show, October 13–15 at Caesars Palace in Las Vegas. American Rebel Light Beer will feature motorsports legend and Hall of Fame driver Tony Stewart at the event.

● CHEK → Holding its Annual General Meeting of Shareholders on October 17, 2025, at 10:00 a.m. ET in New York. Key proposals include approval of a merger with MBody AI, a reverse stock split of ordinary shares (1-for-14 to 1-for-100), re-election of four directors, and a company name change to “MBody AI Ltd.”

● OSTX → Hosting an investor conference call on October 13, 2025, at 8:30 a.m. ET to discuss data from the ongoing Fully Resected Metastatic Osteosarcoma Trial and the regulatory path to conditional marketing authorization for OST-HER2 in the U.S., U.K., and EU.

● MCRP → Announced participation in GITEX GLOBAL 2025, the large-scale tech exhibition in Dubai, from October 13–17, 2025.

● LVO → Collaborating for the #LightUpMBC Live event on October 13, 2025, to benefit METAvivor Research and Support, featuring 270 landmarks worldwide illuminating for Metastatic Breast Cancer Awareness Day.

● LASE → Attending the 44th International Congress on Applications of Lasers and Electro-Optics (ICALEO) from October 13–16 in Orlando, Florida, alongside partner Laser Photonics, showcasing advanced laser and electro-optics technologies.

● BZAI → Participating at GITEX GLOBAL 2025 in Dubai, October 13–17, 2025, a leading tech, AI, and startup exhibition.

● PRSO → Presenting innovative 60 GHz fixed wireless access solutions at WISPAPALOOZA 2025 in Las Vegas, October 13–16, 2025, with company representatives attending.

● LXRX → Lexicon to present additional analyses from its Phase 2 studies and discuss DPNP (diabetic peripheral neuropathic pain) at the Pain Therapeutics Summit, October 13–14, 2025.

● SEER → Participating in the American Society of Human Genetics (ASHG) 2025 Annual Meeting in Boston, October 14–18, 2025, with a featured CoLab session and multiple scientific presentations demonstrating the Proteograph® Product Suite.

● SOAR → Vaunt, the experiential private aviation platform, attending the National Business Aviation Association’s Business Aviation Convention & Exhibition (NBAA-BACE) in Las Vegas, October 14–16, 2025.

● GANX → Hosting a virtual KOL event on October 14, 2025, at 4:00 p.m. EST, discussing biomarkers, clinical endpoints, and emerging data from GT-02287.

● HIT → Showcasing its Enhanced Do It Yourself Benefit System (eDIYBS) at the SIIA National Conference, October 12–14, 2025, in Phoenix, Arizona.

● HOVR → Participating in NBAA-BACE, October 14–16, 2025, in Las Vegas, and Growth Frontiers Americas, October 15–16, 2025, in New York City, with management available for 1x1 meetings at both events.

● AMPG → Announced membership in the ORAN Alliance and Telecom Infra Project (TIP), attending Network X in Paris, France, October 14–16, 2025, showcasing involvement in the ORAN 5G ecosystem.

● ACRS → Hosting its 2025 R&D Day on October 14, 2025, in Midtown New York to discuss progress in therapeutic gaps in immuno-inflammatory markets.

● APYX → Hosting a virtual KOL event on October 14, 2025, at 12:00 PM ET, featuring Paul Vanek, Jr., MD, discussing the commercial launch of the AYON Body Contouring System™.

● EVAX → Attending the World Vaccine Congress Europe in Amsterdam, October 14–16, 2025.

● GCL → Showcasing its latest game, “Island of Hearts,” at gamescom asia x Thailand Game Show 2025 in Bangkok, October 16–19, 2025, offering hands-on demonstrations.

● NTWK → Launching its AI-powered credit decisioning engine, Check AI, at the Auto Finance Summit in Las Vegas, October 15–17, 2025, at Booth 132.

● NRO → Declared a distribution of $0.0312 per share, payable October 31, 2025, with record and ex-dates on October 15, 2025.

● SPRC/NITO → Achieved stockholder approval for the acquisition of MitoCareX Bio Ltd., a subsidiary of SciSparc, clearing a key path for closing in the first half of October 2025.

● EDBL → Showcasing USDA Certified Organic Hydroponic Basil at the Global Produce & Floral Show, October 16–18, 2025, at the Anaheim Convention Center.

● AREC → Hosting The Critical Minerals Forum 2025 on October 16, 2025, at Clifford Chance NY, exploring market outlook, supply chains, and AI in critical minerals.

● IRD → Presenting clinical data from the OPGx-LCA5 Phase 1/2 trial for rare inherited retinal diseases at the American Academy of Ophthalmology (AAO) on October 16, 2025, in Orlando, FL.

● CLLS → Hosting an Investor R&D Day on October 16, 2025, in New York City, presenting Phase 1 data and late-stage strategy for lasme-cel (UCART22) in r/r B-ALL.

● FSP → Declared a quarterly dividend of $0.01 per share for July 1–September 30, 2025, payable November 6, 2025, to stockholders of record as of October 17, 2025.

● GROW → Approved a dividend of $0.0075 per share for October 2025, payable October 27, 2025, with record date October 14, 2025.

● AUUD → Extended exclusivity period for a proposed business combination with Thramann Holdings, LLC, now expiring October 18, 2025.

● COCH → Participating in the AAO-HNSF conference, October 11–14, 2025, in Indianapolis, Indiana, with management available for meetings.

● INO → Presenting INO-3107 clinical data for recurrent respiratory papillomatosis at the AAO-HNS Annual Meeting (Oct 11–13), World Vaccine Congress Europe (Oct 13), and ESMO Congress (Oct 19).

● DWTX → Presenting Halneuron® pain management research at the 19th Annual Pain Therapeutics Summit on October 14, 2025.

● NBY → Hosting its 2025 Annual Meeting of Stockholders on October 16, 2025, in which multiple proposals, including director elections, executive compensation, reverse stock split, and increases to authorized shares, will be voted on.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.